Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

TY - JOUR

T1 - Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

AU - Andersen, Jørn

AU - Kamby, C.

AU - Ejlertsen, B.

AU - Cold, Søren

AU - Ewertz, Marianne

AU - Jacobsen, E.H.

AU - Philip, P.

AU - Møller, K.A.

AU - Jensen, D.

AU - Møller, Susanne

N1 - Times Cited: 2ArticleEnglishAndersen, JArhus Sygehus, Arhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, DenmarkCited References Count: 16315NOTAYLOR & FRANCIS ASPO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAYOSLO

PY - 2008

Y1 - 2008

N2 - From January 1, 1990 to December 31, 1994, DBCG conducted a randomised trial in 1 615 postmenopausal women with operable, high-risk, receptor-positive or -unknown breast cancer. The patients were after surgery randomised to Tamoxifen for 1 year (TAM1), Tamoxifen for 2 years (TAM 2) or Tamoxifen for 6 months followed by megestrol acetate for 6 months (TAM/MA). When the preplanned sample size of 1 500 patients was reached it was decided to continue randomisation to TAM1 or TAM2 and the study was finally closed December 31, 1996. With a median follow-up of more than 10 years, there was no difference in disease-free survival (DFS) or overall survival (OS) among the three treatment arms. Similar results were obtained in the original and extended comparisons of Tamoxifen for 1 versus 2 years. A multivariate analysis in the perprotocol treated patients did not show significant differences in hazard ratios for DFS or OS among the three arms. Sideeffects were rare but more common in the TAM2 and TAM/MA arms Udgivelsesdato: 2008

AB - From January 1, 1990 to December 31, 1994, DBCG conducted a randomised trial in 1 615 postmenopausal women with operable, high-risk, receptor-positive or -unknown breast cancer. The patients were after surgery randomised to Tamoxifen for 1 year (TAM1), Tamoxifen for 2 years (TAM 2) or Tamoxifen for 6 months followed by megestrol acetate for 6 months (TAM/MA). When the preplanned sample size of 1 500 patients was reached it was decided to continue randomisation to TAM1 or TAM2 and the study was finally closed December 31, 1996. With a median follow-up of more than 10 years, there was no difference in disease-free survival (DFS) or overall survival (OS) among the three treatment arms. Similar results were obtained in the original and extended comparisons of Tamoxifen for 1 versus 2 years. A multivariate analysis in the perprotocol treated patients did not show significant differences in hazard ratios for DFS or OS among the three arms. Sideeffects were rare but more common in the TAM2 and TAM/MA arms Udgivelsesdato: 2008

U2 - 10.1080/02841860802014882

DO - 10.1080/02841860802014882

M3 - Journal article

SN - 0284-186X

VL - 47

SP - 718

EP - 724

JO - Acta Oncologica

JF - Acta Oncologica

IS - 4

ER -